- Previous Close
0.0311 - Open
0.0311 - Bid 0.0320 x --
- Ask 0.0845 x --
- Day's Range
0.0311 - 0.0320 - 52 Week Range
0.0202 - 0.1500 - Volume
36,832 - Avg. Volume
8,102 - Market Cap (intraday)
1.011M - Beta (5Y Monthly) 0.08
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1400 - Earnings Date May 27, 2025 - Jun 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Restart Life Sciences Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing diagnostics and psilocybin-based therapeutics for the treatment of neuroinflammatory disorders, including autism spectrum disorder and fragile X syndrome. The company was formerly known as Nova Mentis Life Science Corp. and changed its name to Restart Life Sciences Corp. in November 2024. Restart Life Sciences Corp. was incorporated in 2004 and is based in Vancouver, Canada.
www.restartlife.coRecent News: NMLSF
View MorePerformance Overview: NMLSF
Trailing total returns as of 4/10/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NMLSF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NMLSF
View MoreValuation Measures
Market Cap
635.81k
Enterprise Value
502.11k
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
40.85
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-219.74%
Return on Equity (ttm)
--
Revenue (ttm)
-28.35k
Net Income Avi to Common (ttm)
15.05k
Diluted EPS (ttm)
-0.1400
Balance Sheet and Cash Flow
Total Cash (mrq)
250.59k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-200.21k